Movement Alert｜Abivax S.A. Rises 6.46% in Pre-Market Trading, $920 Million ADS Offering Officially Closes Boosting Bullish Sentiment

Market Focus07-06

On July 6, Abivax S.A. rose 6.46% in pre-market trading, trading at $152.5/share, with turnover of $580,000. The stock continues to trade well above the $125 offering price.

On the news front, the company's $920 million ADS offering officially completed settlement on Monday. Underwriters fully exercised their overallotment option, purchasing an additional 960,000 ADSs, expanding gross proceeds from $800 million to approximately $920 million, with net proceeds of about $874.1 million. The offering was upsized twice from an initial $600 million, reflecting robust institutional demand.

The strong fundraising momentum follows positive Phase 3 ABTECT Maintenance Part 2 topline results for obefazimod in ulcerative colitis, which showed no new safety signals and malignancy rates consistent with expected background rates, effectively resolving prior safety concerns. Net proceeds will support potential US commercialization of obefazimod, clinical research for ulcerative colitis and Crohn's disease, and general corporate purposes. Analysts polled maintain an average buy rating with a mean price target of $148.17.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1120085619?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-06 16:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120085619","market":"us","top_or_hot":-1,"title":"Movement Alert｜Abivax S.A. Rises 6.46% in Pre-Market Trading, $920 Million ADS Offering Officially Closes Boosting Bullish Sentiment","media":"Market Focus","content":"<p><p>On July 6, Abivax S.A. rose 6.46% in pre-market trading, trading at $152.5/share, with turnover of $580,000. The stock continues to trade well above the $125 offering price.</p><p>On the news front, the company's $920 million ADS offering officially completed settlement on Monday. Underwriters fully exercised their overallotment option, purchasing an additional 960,000 ADSs, expanding gross proceeds from $800 million to approximately $920 million, with net proceeds of about $874.1 million. The offering was upsized twice from an initial $600 million, reflecting robust institutional demand.</p><p>The strong fundraising momentum follows positive Phase 3 ABTECT Maintenance Part 2 topline results for obefazimod in ulcerative colitis, which showed no new safety signals and malignancy rates consistent with expected background rates, effectively resolving prior safety concerns. Net proceeds will support potential US commercialization of obefazimod, clinical research for ulcerative colitis and Crohn's disease, and general corporate purposes. Analysts polled maintain an average buy rating with a mean price target of $148.17.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Abivax S.A. Rises 6.46% in Pre-Market Trading, $920 Million ADS Offering Officially Closes Boosting Bullish Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Abivax S.A. Rises 6.46% in Pre-Market Trading, $920 Million ADS Offering Officially Closes Boosting Bullish Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-06 16:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 6, Abivax S.A. rose 6.46% in pre-market trading, trading at $152.5/share, with turnover of $580,000. The stock continues to trade well above the $125 offering price.</p><p>On the news front, the company's $920 million ADS offering officially completed settlement on Monday. Underwriters fully exercised their overallotment option, purchasing an additional 960,000 ADSs, expanding gross proceeds from $800 million to approximately $920 million, with net proceeds of about $874.1 million. The offering was upsized twice from an initial $600 million, reflecting robust institutional demand.</p><p>The strong fundraising momentum follows positive Phase 3 ABTECT Maintenance Part 2 topline results for obefazimod in ulcerative colitis, which showed no new safety signals and malignancy rates consistent with expected background rates, effectively resolving prior safety concerns. Net proceeds will support potential US commercialization of obefazimod, clinical research for ulcerative colitis and Crohn's disease, and general corporate purposes. Analysts polled maintain an average buy rating with a mean price target of $148.17.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABVX","symbol_name":"Abivax S.A.","start_time":0,"source_url":"","article_id":"1120085619","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120085619","pubTimestamp":1783325247,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 6, Abivax S.A. rose 6.46% in pre-market trading, trading at $152.5/share, with turnover of $580,000. The stock continues to trade well above the $125 offering price.On the news front, the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABVX":"Abivax S.A."},"translate_title":"动向提示|Abivax S.A.盘前涨6.46%9.2亿美元ADS发行正式结束提振看涨情绪","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABVX":1},"content_text":"On July 6, Abivax S.A. rose 6.46% in pre-market trading, trading at $152.5/share, with turnover of $580,000. The stock continues to trade well above the $125 offering price.On the news front, the company's $920 million ADS offering officially completed settlement on Monday. Underwriters fully exercised their overallotment option, purchasing an additional 960,000 ADSs, expanding gross proceeds from $800 million to approximately $920 million, with net proceeds of about $874.1 million. The offering was upsized twice from an initial $600 million, reflecting robust institutional demand.The strong fundraising momentum follows positive Phase 3 ABTECT Maintenance Part 2 topline results for obefazimod in ulcerative colitis, which showed no new safety signals and malignancy rates consistent with expected background rates, effectively resolving prior safety concerns. Net proceeds will support potential US commercialization of obefazimod, clinical research for ulcerative colitis and Crohn's disease, and general corporate purposes. Analysts polled maintain an average buy rating with a mean price target of $148.17.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1120085619","isCrawlerRequest":true}